We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

WETO:NASDAQWetour Robotics Limited Analysis

Data as of 2026-06-15 - not real-time

$1.01

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Wetour Robotics (WETO) trades at $1.01, roughly 2.7× its book value and 3× its sales, while posting negative gross (14%) and operating margins and an EBITDA loss of $18.4 M. The technical picture is mixed: the price sits above the 20‑day SMA (0.96) and the 200‑day SMA (0.998), RSI is at 60 indicating modest bullish pressure, yet the MACD histogram is slightly negative and volume is trending down, suggesting weakening momentum. The stock’s beta of ~1.03 and a 30‑day volatility of 122% point to a highly volatile, near‑market‑neutral trend.
Fundamentally, the company is cash‑starved, with $1.3 M cash against $23 M debt (D/E ≈ 52) and a massive free‑cash‑flow deficit of $35 M, while revenue shrank 45% YoY. Recent press releases tout the “Orchestra” AI‑driven wearable platform and highlight partnerships with Qualcomm, but no earnings guidance or analyst coverage is available, leaving commercial traction unproven. Given the extreme greed sentiment in the broader market (Fear‑Greed Index 89.9), the stock appears over‑priced relative to its financial health, and the lack of dividend further diminishes income appeal.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 4/10

Key Factors

  • Price above short‑term moving averages but bearish MACD histogram
  • RSI above 50 showing modest bullish pressure
  • Decreasing volume indicating waning buying interest

Medium Term

1–3 years
Cautious
Model confidence: 5/10

Key Factors

  • Continued cash burn and negative free cash flow
  • High debt load relative to cash and equity
  • Absence of earnings and analyst coverage

Long Term

> 3 years
Cautious
Model confidence: 6/10

Key Factors

  • Unproven commercial adoption of the Orchestra platform
  • Potential financing constraints given current balance sheet
  • Extreme market greed may inflate price temporarily, but fundamentals remain weak

Key Metrics & Analysis

Financial Health

Revenue Growth-45.00%
Profit Margin-75.88%
ROE-60.52%
ROA-19.31%
Debt/Equity51.62
P/B Ratio2.7
Op. Cash Flow$-39541028
Free Cash Flow$-35448932
Industry P/E36.8

Technical Analysis

TrendNeutral
RSI60.3
Support$0.51
Resistance$1.21
MA 20$0.96
MA 50$0.69
MA 200$1.00
MACDBearish
VolumeDecreasing
Fear & Greed Index89.86

Valuation

GradeOvervalued
TypeBlend

Risk Assessment

Beta1.03
Volatility122.07%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.